Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Retatrutide vs Liraglutide

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Liraglutide has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Retatrutide

Phase 3

Liraglutide

FDA-Approved

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Retatrutide Liraglutide
Class GIP/GLP-1/glucagon triple agonist GLP-1 receptor agonist
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects GLP-1R agonist; albumin-binding fatty acid extends half-life
Route SC injection SC injection
Half-life ~6 days ~13 hrs
Dosage (research) 2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk) 0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label)
Evidence tier Phase 3 FDA-Approved
Research depth 217 indexed (PubMed 159 · CT 33 · EPMC 25) 321 indexed (PubMed 197 · CT 69 · EPMC 55)
Availability Investigational Prescription
Reported risks GI side effects; Phase 3 ongoing; long-term safety unknown Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Retatrutide or Liraglutide?

Liraglutide has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Retatrutide and Liraglutide?

Retatrutide is classed as GIP/GLP-1/glucagon triple agonist; Liraglutide is classed as GLP-1 receptor agonist. Reported mechanism: Retatrutide, Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects; Liraglutide, GLP-1R agonist; albumin-binding fatty acid extends half-life. Reported half-life: Retatrutide, ~6 days; Liraglutide, ~13 hrs. Routes in published studies: Retatrutide, SC injection; Liraglutide, SC injection.

Which has stronger evidence, Retatrutide or Liraglutide?

Liraglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Retatrutide is graded Phase 3, with 29 cited sources on its reference page and 217 indexed studies. Liraglutide is graded FDA-Approved, with 64 cited sources on its reference page and 321 indexed studies.

Which is more accessible, Retatrutide or Liraglutide?

Liraglutide is FDA-approved and Retatrutide is not. Catalog status: Retatrutide, Investigational; Liraglutide, Prescription.

Are Retatrutide and Liraglutide ever combined?

Retatrutide and Liraglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…